SOUL trial preliminary data — semaglutide in T2DM cardiovascular outcomes

Great question. CVOT stands for Cardiovascular Outcomes Trial. Here's the backstory:

In 2008, the FDA mandated that all new diabetes drugs must demonstrate cardiovascular safety before approval — meaning they can't increase heart attack or stroke risk. This was a response to the rosiglitazone controversy, where a diabetes drug was found to increase MI risk.[5]

So every new diabetes drug needs a large, long-term randomized trial measuring "MACE" — major adverse cardiovascular events (heart attack, stroke, cardiovascular death) — to prove it doesn't cause harm (the upper bound of the 95% CI for the hazard ratio must be <1.3).

What makes SELECT, LEADER, SUSTAIN-6, and now SOUL special is that they went beyond proving safety and actually demonstrated cardiovascular superiority — meaning GLP-1 RAs actively reduce heart attacks and strokes compared to placebo. That transforms these drugs from "diabetes medications that happen to cause weight loss" into "cardiovascular risk reduction agents that also treat diabetes and obesity."

SOUL doing this for the oral formulation means doctors can now prescribe a pill (not a shot) with proven CV protection. That's a much easier conversation with patients.

One final point that hasn't been discussed: the renal outcomes from SOUL. The composite kidney endpoint hit significance — HR 0.78 (95% CI: 0.63-0.97). This includes sustained eGFR decline >=50%, ESKD, renal death, and sustained eGFR <15.

This is important context alongside the FLOW trial, which studied injectable semaglutide specifically for diabetic kidney disease and showed a 24% reduction in kidney disease progression.[6] SOUL now provides supporting evidence that even oral semaglutide at the lower 14mg dose has renal protective effects.

The renal story is mechanistically interesting: GLP-1R is expressed in the kidney (proximal tubule, glomerular afferent arteriole), and GLP-1 RA-mediated natriuresis and reduced intraglomerular pressure may contribute to nephroprotection independent of glycemic control or weight loss. This is analogous to SGLT2 inhibitor renal mechanisms, and the two drug classes likely have complementary nephroprotective effects.

SOUL positions oral semaglutide as a triple-threat: glycemic control + cardiovascular protection + renal protection, all in a once-daily pill. That's a compelling value proposition for the T2DM population.

To summarize the state of play for clinical decision-making:

GLP-1 RA formulations with CVOT superiority data:

• Liraglutide SC 1.8mg — LEADER (2016): HR 0.87 for 3P-MACE
• Semaglutide SC 0.5/1.0mg — SUSTAIN-6 (2016): HR 0.74 (pre-approval, smaller trial)
• Dulaglutide SC — REWIND (2019): HR 0.88 (included primary prevention patients)
• Semaglutide SC 2.4mg — SELECT (2023): HR 0.80 (non-diabetic obesity)
• Semaglutide oral 14mg — SOUL (2025): HR 0.86

GLP-1 RAs with CVOT safety but NOT superiority:

• Exenatide ER — EXSCEL: HR 0.91 (p=0.06, missed significance)
• Lixisenatide — ELIXA: HR 1.02 (neutral)

The class effect for cardiovascular benefit is now established for longer-acting GLP-1 RAs. The SOUL result fills in a critical gap by extending this to the oral formulation, which dramatically broadens the eligible patient population.

The remaining question is whether oral semaglutide at higher doses (25-50mg) would provide even greater CV and weight loss benefit. That's a trial someone should run — though given the competitive landscape, Novo may prioritize amycretin development instead.